The fatigue experienced by most patients with multiple sclerosis (MS) is much more intense than general fatigue, underscoring the importance of utilizing effective management strategies like therapies, exercise, and reward-based interventions. Here to discuss these particular techniques for managing MS-related fatigue is Dr. Glenn Wylie, Director of the Rocco Ortenzio Neuroimaging Center at Kessler Foundation and a Professor at Rutgers - New Jersey Medical School.
Managing MS-Related Fatigue with Therapeutic, Lifestyle, and Behavioral Interventions

Transcript
Managing MS-Related Fatigue with Therapeutic, Lifestyle, and Behavioral Interventions
closeTranscript
Managing MS-Related Fatigue with Therapeutic, Lifestyle, and Behavioral Interventions
closeAnnouncer:
You’re listening to On the Frontlines of Multiple Sclerosis on ReachMD. On this episode, Dr. Glenn Wylie will share strategies for managing fatigue in patients with multiple sclerosis. Not only is Dr. Wylie the Director of the Rocco Ortenzio Neuroimaging Center at Kessler Foundation, but he’s also a Professor at Rutgers - New Jersey Medical School. Here he is now.
Dr. Wylie:
So MS-related fatigue differs from general fatigue, I think, in quantity rather than in quality. Folks with MS have a lot of fatigue—almost everyone experiences really high levels of fatigue because they have MS—but I think that the fatigue that is experienced in MS is similar to and is generated by the same mechanisms as the fatigue that is experienced by the general population. I think that fatigue really is an imbalance between effort and reward, and I think that fatigue is the brain’s way of telling itself that the reward it’s getting for a given action is no longer worth the effort that it has to expend to do that action. And if you have a neurodegenerative disease like MS, then everything that you have to do takes more effort.
So are there any effective management techniques for fatigue based on current research? We’ve been doing some research in this area, and some of the things we’ve been looking at are pharmaceutical interventions and whether disease-modifying therapies reduce fatigue measurably, and we’re finding that they do. They seem to reduce the baseline level of fatigue in folks with MS, so that’s promising. It’s very early in the research process, but it’s promising.
We’ve also looked at the effect of exercise on fatigue, and that seems to reduce fatigue. Of course, exercise in the short term makes you fatigued; you end up being physically fatigued after you exercise. But in the longer term, it seems to have beneficial effects where, again, it sort of moves the baseline level of fatigue down. And then the other thing we’ve looked at has to do with this idea of effort and reward, and we’ve looked at if you give someone rewards for doing something, does that reduce their fatigue? And that seems to work as well.
Announcer:
That was Dr. Glenn Wylie talking about the management of fatigue in multiple sclerosis patients. To access this and other episodes in our series, visit On the Frontlines of Multiple Sclerosis on ReachMD.com, where you can Be Part of the Knowledge. Thanks for listening!
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
The fatigue experienced by most patients with multiple sclerosis (MS) is much more intense than general fatigue, underscoring the importance of utilizing effective management strategies like therapies, exercise, and reward-based interventions. Here to discuss these particular techniques for managing MS-related fatigue is Dr. Glenn Wylie, Director of the Rocco Ortenzio Neuroimaging Center at Kessler Foundation and a Professor at Rutgers - New Jersey Medical School.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
How COVID-19 Is Affecting Life Outside of the Office: A Dermatologist’s Experience
Finding the Patient With PH Among Us: How We Optimize Treatment Based on Patient Type
Implementing the AMA MAPTM Hypertension Program: A Clinician’s Experience
Application of guidelines-recommended broad molecular profiling to patients with NSCLC
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
Personalizing Care Within the RCC Treatment Paradigm
Navigating Myasthenia Gravis in Adolescents and Young Adults
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?